Evidence supporting the use of: Nicotinamide Adenine Dinucleotide
For the health condition: Parkinson's Disease

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Nicotinamide Adenine Dinucleotide (NAD+) is a critical coenzyme involved in cellular energy metabolism and mitochondrial function. In Parkinson’s Disease (PD), neurodegeneration is associated with mitochondrial dysfunction and impaired cellular energy production. Preclinical studies suggest that boosting NAD+ levels may protect against neuronal loss by enhancing mitochondrial function and reducing oxidative stress. Some research in cellular and animal models of PD has shown that NAD+ precursors (such as nicotinamide riboside or nicotinamide mononucleotide) can improve mitochondrial health and decrease neurodegenerative processes. However, robust clinical evidence in humans is lacking. Only a small number of early-phase clinical trials and case reports have explored the potential benefits of NAD+ supplementation in PD, and these studies are generally limited by small sample sizes, open-label designs, and short durations. To date, NAD+ supplementation is not an established or approved therapy for Parkinson’s Disease, and major neurological or movement disorder societies do not endorse its use outside research settings. In summary, while there is a plausible scientific rationale and encouraging preclinical data, high-quality human research is still required to establish the efficacy and safety of NAD+ supplementation in the treatment or support of Parkinson's Disease.

More about Nicotinamide Adenine Dinucleotide
More about Parkinson's Disease

Products containing Nicotinamide Adenine Dinucleotide

We currently have no products on Vitabase that contain this ingredient.